Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination TherapyCourtney V. Fletcher, Mark W. Kline, Richard C. Brundage et al.|Antimicrobial Agents and Chemotherapy|2000Cited by 69
A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virusMark W. Kline, Cara Simon, Nancy R. Calles et al.|The Journal of Pediatrics|1998Cited by 60
Isolation of <i>Lautropia mirabilis</i> from Oral Cavities of Human Immunodeficiency Virus-Infected ChildrenSusan Rossmann, Mark W. Kline, Patricia H. Wilson et al.|Journal of Clinical Microbiology|1998Cited by 36
Oral Manifestations of Pediatric Vertical HIV InfectionClaudia A. Kozinetz, Mark W. Kline, A B Carter et al.|AIDS Patient Care and STDs|2000Cited by 29
Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudineMark W. Kline, Heidi Schwarzwald, Nancy R. Calles et al.|The Pediatric Infectious Disease Journal|2000Cited by 11